



93726835

Relais Request No. REG-29707584
Customer Code
03-0018

Delivery Method
Ariel

Request Number
675015/CAMPYL FXBK99 S S

Scan

Date Printed: 28-Jul-2011 07:48
Date Submitted: 27-Jul-2011 06:08

3016.406110

TITLE: CAMPYLOBACTER V : PROCEEDINGS OF THE
YEAR: 1989
VOLUME/PART:
PAGES:
AUTHOR:
ARTICLE TITLE:
SHELFMARK: 3016.406110

DOCUMENT DELIVERY IRAM
Ariel Address: dd-ariel@library.uwa.edu.au

Your Ref :

675015/CAMPYL FXBK99 S S|CAMPYLOBACTER V : PROCEEDINGS OF THE|FIFTH
INTERNATIONAL WORKSHOP ON|RUIZ-PALACIOS, G M. ED.|1991. VOL 5TH 1989|PP 270-?
CAMPYLOBACTER PYLORI THERAPY.|MARSHALL BJ, BARRETT LJ,|INSTITUTO NACIONAL DE

DELIVERING THE WORLD'S KNOWLEDGE

This document has been supplied by the British Library www.bl.uk

Copyright Statement

Unless out of copyright, the contents of the document(s) attached to or accompanying this page are protected by copyright. They are supplied on condition that, except to enable a single paper copy to be printed out by or for the individual who originally requested the document(s), you may not copy (even for internal purposes), store or retain in any electronic medium, retransmit, resell, hire or dispose of for valuable consideration any of the contents (including the single paper copy referred to above). However these rules do not apply where:

1. You have the written permission of the copyright owner to do otherwise;
2. You have the permission of The Copyright licensing Agency Ltd, or similar licensing body;
3. The document benefits from a free and open licence issued with the consent of the copyright owner;
4. The intended usage is covered by statute.

Once printed you must immediately delete any electronic copy of the document(s). Breach of the terms of this notice is enforceable against you by the copyright owner or their representative.

The document has been supplied under our Library Privilege service. You are therefore agreeing to the terms of supply for our Library Privilege service, available at :

<http://www.bl.uk/reshelp/atyourdesk/docsupply/help/terms/index.html>

Campylobacter pylori Therapy: is *in vitro* Disc Testing with Metronidazole Worthwhile?

B.J. Marshall, L.J. Barrett, R.W. McCallum, R.L. Guerrant

University of Virginia, Charlottesville, VA.

C. pylori may be treated with bismuth and metronidazole combinations. The aim of this study was to prospectively evaluate Cp isolates for metronidazole sensitivity using 5 µg discs, and to correlate this with the result of therapy. Data were available from 26 consecutive patients, in whom disc testing had been performed on their *C. pylori* isolates. Patients were then treated with 14 days of bismuth subsalicylate (BSS) 500 mg QID AC and were given metronidazole 1-1.5 mg daily (20 mg/kg/d), between day 4 and day 14. Biopsy was repeated one month after therapy, to confirm eradication of the organism. Antral biopsies were cultured on horse blood agar plates with GCHI supplement (REMEL) for 3 days in a 10% CO₂ incubator. Cp isolates were picked and cultured in the same manner in the presence of a 5 mm diameter 5 microgram metronidazole disc, zone diameters were measured after 3-5 days. Treatment was successful in 19 patients (73%). The mean zone diameter in isolates, from successfully treated patients, was 26.6 mm, SD 14 mm. The mean zone size from patients who failed therapy was 16 mm, SD 14 mm (p=0.1). When the zone diameter was ≥ 15 mm the cure rate was 89%. When the zone size was <15 mm, the cure rate was only 37%. The data suggests that nitroimidazole disc sensitivities can predict the outcome of bismuth/nitroimidazole therapy. We are also comparing methods if sensitivity testing for *C. pylori* which show a correlation of disc and agar dilution techniques.

Introduction

C. pylori may be treated with bismuth and metronidazole combinations with a cure rate of about 75%. About 25% of *C. pylori* isolates are resistant *in vitro* to nitroimidazoles but *in vitro* sensitivity testing has not been proven to be a useful guide to therapy in the United States. The aim of this study was to prospectively evaluate CP isolates for metronidazole susceptibility using 5 µg discs, and to correlate this with the result of therapy.

Subjects and Methods

Patients were diagnosed as having *C. pylori* by rapid urease test (CLO-test) of a gastric mucosal biopsy specimen. If *C. pylori* was present, therapy commenced with bismuth subsalicylate (BSS) 500 mg QID, 30-60 min before meals and at bedtime. After 4-7 days metronidazole was added in a dose of approximately 20 mg/kg/day. BSS and metronidazole were taken concurrently for a further 10 days. Biopsy was repeated, or a ¹⁴C-urea breath test was performed, 28 days after completing therapy.

To perform *in vitro* sensitivity testing, antral biopsies were cultured on horse blood agar with GCHI supplement (Regional Media Laboratories, Lanexa, Kansas) for 3 days in a 10% CO₂ incubator. *C. pylori* isolates were picked and grown in the same manner, but in the presence of a 5 µg metronidazole disc (diameter 5 mm). Inhibition zone diameter was measured after 3-5 days.

Results

Follow-up data were available from 34 consecutive patients in whom *C. pylori* had been cultured and disc testing had been performed either on the initial or follow-up isolate. *C. pylori* could not be detected in 19 patients after therapy. The mean zone diameter in isolates from these successfully treated patients was 25.6 mm, s.e.m. 2.5 mm. In contrast, the mean zone diameter of 15 patients in whom *C. pylori* was still present was 7.9 mm, s.e.m. 3.4mm (Table 1).

Note that when the zone diameter was ≥ 15 mm, the cure rate was 94% (16/17). When the zone size was < 15 mm, the cure rate was only 18%. The difference was highly significant (p=0.00001 Fisher's exact test).

Conclusions+

1. Metronidazole disc sensitivities can predict the outcome of BSS/metronidazole therapy.
2. Cure rate approaches 100% when the isolate is sensitive *in vitro*.
3. It is probably useless to give a nitroimidazole when the *C. pylori* isolate is resistant *in vitro*.

Table

ZONE DIAMETER (mm): (disc diam. = 5mm)	SUCCESSFUL THERAPY	
	FAILED THERAPY	
no zone seen	13	2
6-14mm	1	1
15-29 mm	0	7
≥30 mm	1	9